Bill Lazonick is an economist who researches and writes on the social foundations of innovative enterprise and is a critic of the financialized corporation.
A free download of the pdf of my book, Investing in Innovation: Confronting Predatory Value Extraction in the US Corporation is available until September 9:
https://t.co/896OquMnp6
Matt Hopkins and I have just published our article on Elon Musk's "pay" package: Elon Musk’s latest power grab: Will Tesla’s CEO become the world’s first trillion-dollar employee?
https://t.co/rX8WPBrBBg
so stoked for our next releases
@AndrewBCollins about how the Tas Tepeler civilization gave birth to the serpent myth that carries through to modern day
@Lazonick with a breakneck tour of the fallout from forty years unregulated corporate raiding. Live for patrons now 🫳👇
Why is nobody talking about the fact that #USSteel authorized hundreds of millions in stock buybacks even as their executives said they needed investment from #nipponsteel to upgrade their obsolescent plant and equipment? https://t.co/BUrLLtlpYl @Lazonick
INET just posted the Tulum-Lazonick paper, "Setting Pharmaceutical Drug Prices":
https://t.co/iPQCprQUFQ
It is summarized in our article, “What is ‘Fair' Drug Price?”: https://t.co/iukdhbBodO
New working paper, Hopkins and Lazonick, "Tesla as a Global Competitor": https://t.co/8jTV1rzcZX; and our article on how Elon Musk secures strategic control at Tesla: https://t.co/C8f7jUFscN
@tmothergoddess The 8/7/19 tweet led to securities fraud charges. Even if that is no longer a problem, it is now too expensive. In 8/19 the cost at $420/share ($28 split adjusted) would have been $71 billion. Now TSLA market cap is $586 billion.
@rgmcgrath The paper, co-authored with Marie Carpenter, is "The Pursuit of Shareholder Value: Cisco's Transformation from Innovation to Financialization," Institute for New Economic Thinking Working Paper, February 2023: https://t.co/s80bD88B1i
@MazzucatoM@twhitfill The complete analysis of the financialization of US pharma is in Lazonick and Tulum, "Sick with 'Shareholder Value': US Pharma's Financialized Business Model During the Pandemic," Academic-Industry Research Network, https://t.co/fFMwuJ8hUJ (published in Competition & Change).
You know that sneaking feeling that something is way out of whack in our economy? Pop in to this replay of my fascinating conversation with @Lazonick to unpack some of the reasons https://t.co/vnEOOUWQF7
See the latest from Matt Hopkins, William Lazonick
How GM’s $10-Billion Buyback May Ice Its EV Transition | Institute for New Economic Thinking https://t.co/WnzggHX75e #inet
@edieocre@newrepublic What the UAW and Everyone Else Need to Know About CEO Pay
Matt Hopkins and I have just published this article that should be of interest to you:
https://t.co/LoCS446DxP
@MindaZetlin@Inc I see that you wrote about CEO pay in the context of the UAW strike.
Matt Hopkins and @Lazonick have just published this article that should be of interest to you.:
https://t.co/LoCS446DxP
Best
Bill Lazonick
William Lazonick
President, The Academic-Industry Research Network
@RBReich Bob, The CEO pay numbers that almost everyone uses are not what US CEOs actually get paid. In 2022. Mary Barra actually took home $34.1 million. In 2021, it was $62.3 million. See the article @INETeconomics https://t.co/LoCS446DxP